In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner

Quantitative proton magnetic resonance spectroscopy of the normal liver and malignant hepatic lesions at 3.0 Tesla

This comparative study of tumour patients and volunteers aimed at differentiating liver parenchyma from neoplastic lesions by using localised (1)H MRS at 3.0 T as an adjunct to MRI. In total 186 single-voxel proton spectra of the liver were acquired at 3.0 T using the body transmit receive coil. Consecutive stacks of breath-hold spectra were acquired in the PRESS technique at a short echo time of 35 ms and a repetition time of 2,000 ms. Processing of the spectra included spectral alignment with the software package SAGE and quantitative processing with LCModel. The resulting metabolite concentrations were presented in arbitrary units relative to the internal water. In general, the spectra showed four main groups of resonances originating from the methyl protons (0.8-1.1 ppm) and methylene protons of the lipids (1.1-1.5 ppm; 2.0-2.2 ppm) as well as the methyl protons of choline-containing compounds (CCC) at 3.2 ppm. Overall, the CCC and lipid values in malignant liver tumours showed no significant differences to liver parenchyma. On average, total lipid measurements in normal liver parenchyma increased with age, while those of the CCC did not show pertinent changes. Significant differences between the contents of CCC in malignant liver tumours and normal liver parenchyma were not observed, because in patients and volunteers normal liver tissue showed a large variability in the content of CCC.

Progress in application of high-field-strength MR to diagnosis and treatment of hepatocellular carcinoma

Magnetic resonance imaging (MRI), a modern imaging modality, cannot only diagnose diseases, but also participate in their treatment. With the increase in static magnetic field strength, the features of high-field-strength MRI become increasingly predominant, thus MRI has been widely used in the diagnosis and treatment of diseases. MRI at high field strength can provide information on abnormal function and metabolism, monitor therapeutic procedures and reactions, and present excellent morphologic images for hepatocellular carcinoma.

Assessment of in vivo 1H magnetic resonance spectroscopy in the liver: a review

With increased availability of magnetic resonance (MR) systems at ultra-high field strength for clinical studies, other organs besides the brain have received renewed consideration for MR spectroscopy (MRS). Because signal-to-noise ratio and chemical shift increase proportional to the static magnetic field, a concomitant increase in signal intensity and spectral resolution of metabolite resonances can be exploited. Improved resolution of adjacent metabolite peaks would not only provide for more accuracy of metabolite identification but also metabolite quantification. While the superiority of high-field imaging and spectroscopy has already been demonstrated clearly in the brain, this article reviewed issues around 1H MRS of the liver. These include optimization strategies such as coil technology, minimizing of motion artefacts using breath-holding and postprocessing of the spectra. Moreover, we reviewed the pertinent experience hitherto reported in the literature on potential clinical issues where liver MRS may be useful. These included determination and characterization of liver fat content, liver tumours and focal lesions. While these applications have been used experimentally, liver MRS does not yet have a clearly defined role in the clinical management of any disease state. Accordingly, it remains primarily a research modality to date.

Technology of in vivo two-dimension multi-voxel 1H magnetic resonance spectroscopy for rabbit liver VX2 tumor

AIM: To investigate the best techniques of in vivo two-dimension multi-voxel ¹H magnetic resonance spectroscopy (2D ¹H-MRS) for rabbit liver VX2 tumor.

METHODS: The liver of 8 New Zealand white rabbits was implanted directly and respectively with VX2 tumor lump after abdominal cavity was opened. 2D ¹H-MRS acquisition in vivo and unenhanced MRI was performed respectively from the 2^nd week to 4^th week after VX2 tumor was implanted. With knee coil, in vivo 2D ¹H-MRS acquisitions were performed respectively with different TR, different TE and different NEX at 1.5 T MR scanner when other parameters were the same. The distinction between groups was analyzed by SPSS11.0 with baseline and signal-noise ratio (SNR).

RESULTS: From the qualified MRS spectrum, there were up to 6 peaks which could be identified: methyl lipids (Lip1), methylene lipids (Lip2), methylene lipids with double carbon bond (Lip3), glutamine and glutamate complex (Glx), Choline (Cho), and glycogen and glucose complex (Glyu). Baseline and SNR had no significant differences between TR = 1000 ms, 2000 ms and 3000 ms. Baseline had no significant difference between TE = 30 ms and 144 ms. Except that SNR of Glx with 30 ms in TE was higher than that with 144 ms in TE (1.95 ± 0.36 vs 1.24 ± 0.26, P < 0.05), SNR of other metabolites were similar. With NEX increasing, the distinctions of baseline between NEX = 4, 8 and 16 were significant (χ² = 10.000, P < 0.01). SNR of all metabolites increased when NEX was increased gradually. Both of baseline and SNR were the best when NEX was 16.

CONCLUSION: It's practical of in vivo two-dimension multi-voxel ¹H-MRS on the rabbit liver VX2 tumor by a 1.5 T MR scanner. Immobilization, pre-scan (reaching FWHM ≤ 10 Hz and WS ≥ 98%), knee coil, TR = 1000 ms, TE = 30 ms and NEX = 16 may be the best to acquire highly qualified spectra.

Usefulness of chemical-shift MRI in discriminating increased liver echogenicity in glycogenosis

BACKGROUND

Glycogen storage diseases are inherited defects which cause accumulation of glycogen in the tissues. Hepatic steatosis is defined as accumulation of fat within hepatocytes. On sonography, liver shows increased echogenicity both in glycogen storage diseases and steatosis. Liver hyperechogenicity in glycogen storage diseases may depend on accumulation of glycogen and/or fat. Chemical-shift magnetic resonance imaging can discriminate tissues only containing water from those containing both fat and water.

AIM

The primary aim of the present study was to evaluate the usefulness of liver chemical-shift magnetic resonance imaging for detecting liver steatosis in patients with metabolic impairment due to glycogen storage diseases.

SUBJECTS

Twelve patients with type I (n=8) or type III (n=4) glycogen storage diseases were studied and compared to 12 obese-overweight subjects with known liver steatosis. As control group 12 lean normal voluntary subjects were recruited.

METHODS

Liver was evaluated by sonography and chemical-shift magnetic resonance imaging to calculate hepatic fat fraction.

RESULTS

A significant difference in echogenicity between patients with glycogen storage diseases and normal subjects was observed (p<0.05), while this difference was not present between overweight-obese and glycogen storage diseases patients. On the contrary, fat fraction was similar between glycogen storage diseases patients and normal subjects and different between glycogen storage diseases patients and overweight-obese (p<0.05).

CONCLUSION

The present data suggest that chemical-shift magnetic resonance imaging may exclude fat deposition as a cause of liver hyperechogenicity in subjects with glycogen storage diseases.

In vivo 1H MR spectroscopy in the evaluation of the serial development of hepatocarcinogenesis in an experimental rat model

RATIONALE AND OBJECTIVES

We used a 1.5-T MR scanner to investigate in vivo hydrogen 1 ((1)H) MRS to evaluate metabolic changes in the hepatocarcinogenesis experimental rat model.

MATERIALS AND METHODS

Hepatocellular carcinoma (HCC) was induced by diethylnitrosamine in 70 treated rats with 20 normal rats used as controls. Single-voxel (1)H MRS is performed to obtained the relative choline-to-lipid (Cho/lipid) ratio. The liver and tumor tissues are incised for the histologic examination. Based on the histologic result, the progression of hepatocarcinogenesis of the animal model was divided into three stages: fibrosis stage, cirrhosis stage, and HCC stage. The mean (+/-SD) ratio values are calculated and compared at various stages between the treated group and the control group.

RESULTS

In control group, the calculated mean (+/-SD) Cho/lipid ratio was 0.15 +/- 0.05. With the progression of hepatocarcinogenesis, the Cho/lipid ratio increased significantly, to 0.18 +/- 0.05, 0.24 +/- 0.07, and 0.38 +/- 0.19, respectively.

CONCLUSION

The (1)H MRS is technically feasible for evaluation of the metabolic changes in the animal model. A significant increase in choline-containing compounds level was observed in the HCC stage in the treated group.

Early response of hepatocellular carcinoma to transcatheter arterial chemoembolization: choline levels and MR diffusion constants--initial experience

PURPOSE

To prospectively investigate the apparent diffusion coefficient (ADC) and choline levels measured at hydrogen 1 ((1)H) magnetic resonance (MR) spectroscopy, to monitor therapeutic responses of hepatocellular carcinoma (HCC) to transcatheter arterial chemoembolization (TACE).

MATERIALS AND METHODS

Institutional review board approval was obtained, and all patients and control subjects provided informed consent. Histologically proved large HCCs (>3 cm in diameter) were evaluated in 20 patients (16 men and four women; mean age, 59 years; range, 34-80 years) before TACE and 2-3 days after TACE. A control group of eight adults (five men and three women; mean age, 43 years; range, 24-76 years) with normal livers was examined by using the same protocol. Hepatic choline levels were measured by means of an external phantom replacement method, quantifying the peak at 3.2 ppm at (1)H MR spectroscopy. ADCs were measured for all lesions. A Wilcoxon rank sum test was used to compare absolute choline concentrations and ADCs at baseline between HCCs and normal liver parenchyma. Changes in choline levels and ADCs in the tumors before and after TACE were analyzed by using the Wilcoxon signed rank test.

RESULTS

The median preoperative choline level in patients with HCC (measured in 18 of the 20 patients) was 4.0 mmol/L (range, 0.0-17.2 mmol/L), which was significantly higher than that in patients with normal livers (n = 8) (median, 1.6 mmol/L; range, 0.0-2.1 mmol/L; P < .01). Among 18 patients with HCC, choline levels decreased significantly from before TACE to after TACE (P < .01). A significant increase in ADC from before TACE to after TACE in the 20 patients with HCC was also found (P < .01).

CONCLUSION

Hepatic choline levels and ADCs may allow monitoring of therapeutic responses of HCC to TACE although larger, more definitive and quantitative studies with clinical end points are needed.

In vivo detection of metabolic changes by 1H-MRS in the DEN-induced hepatocellular carcinoma in Wistar rat

PURPOSE

To investigate the serial changes of the hepatic metabolites in a chemical-induced rat model of hepatocellular carcinoma (HCC) in vivo by a clinical 1.5 T MR scanner.

METHODS

Diethyl nitrosamine (DEN) induced HCC model rats (n=60) and control rats (n=20) were included. From week 7 to week 20 after DEN administration, every other week 10-12 animals (8-9 treated and 2-3 controls) were randomly scanned before being sacrificed. According to the pathologic changes, the whole process of tumorigenesis was divided into early and late periods (week 7-13 and week 14-20, respectively). The serial hepatic changes were tested by both routine MRI and single voxel 1H-MRS and compared with pathological results. Point resolved spectroscopy sequence (PRESS) was used for the location in MRS. The integrations of lipid- and choline-containing metabolites were calculated and analyzed.

RESULTS

All of the listed tests were fully finished in 66 rats (48 treated and 18 controls). Of the MRS curves, 65.2% (43/66) could be analyzed (mainly with resistant baseline with peaks appearing at right positions). From those qualified MRS curves, there were up to seven peaks which could be identified. The peaks of methylene lipids and methyl lipids were combined together in most cases and became the most notable component. The relative integrals of the combined lipid peak and that of the choline-containing compounds in different groups and stages were measured. Comparing with that of the controls of the same stage, the lipid of treated rats decreased in the late stage, and the choline-containing compounds increased in the same stage. Statistically significant differences were found (P<0.05) for the integrals of the lipid and the choline-containing metabolites between treated and controls in the late stage.

CONCLUSIONS

Our initial studies for the integrals of the lipid compounds and the choline-containing metabolites might be useful for a better understanding of the metabolic activity of this DEN-induced rat HCC model.

Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T

The quantification of choline-containing compounds (Cho) in hepatic tumors by (1)H MR spectroscopy (MRS) is of great interest because such compounds have been linked to malignancy. In this study, a practical external phantom replacement method for the absolute quantification of hepatic metabolites is demonstrated. We performed experiments at 3 T using a body coil, and used an external phantom containing choline chloride for calibration. We first tested the quantification strategy to confirm its suitability in vivo using a phantom of known concentration and normal brain tissue. The results obtained after coil loading and T(1) and T(2) effects were corrected for were consistent with the known concentration and previously published values. To demonstrate its feasibility, we applied the technique to liver studies conducted on five normal volunteers and four patients with hepatocellular carcinoma, and one patient (also in the latter group) who had undergone post-transcatheter arterial chemoembolization (TACE). The Cho concentrations in the four patients were estimated to be 3.4, 6.3, 7.4, and 14.0 mM, respectively. These values are substantially higher than those obtained from the healthy volunteers (1.3 +/- 0.9 mM (mean +/- SD)). The results indicate that the proposed method is accurate and requires fewer tedious procedures for MRS; therefore, it may be a promising technique for evaluating response to treatment in liver cancer.

Proton and phosphorus-31 nuclear magnetic resonance spectroscopy of human bile in hepatopancreaticobiliary cancer

OBJECTIVE

Hepatopancreaticobiliary cancers can be difficult to diagnose. Nuclear magnetic resonance (NMR) spectroscopy provides non-invasive information on phospholipid metabolism, and previous studies of liver tissue have highlighted changes in phospholipids in malignancy. We hypothesised that in-vitro NMR spectroscopy of human bile may provide independent diagnostic indices in cancer management through an assessment of the phospholipid content.

DESIGN AND METHODS

Bile samples from 24 patients were collected at endoscopic retrograde cholangiopancreatography and from one subject at cholecystectomy. Thirteen patients had cancer: pancreatic carcinoma (eight), cholangiocarcinoma (three) and metastatic liver disease (two). The remaining 12 patients had non-malignant pathology. In-vitro proton (H) and phosphorus-31 (P) NMR spectra were obtained from all samples using an 11.7 Tesla NMR spectroscopy system.

RESULTS

Complementary information was obtained from the H and P NMR spectra. Signals were assigned to phosphatidylcholine in both H and P NMR spectra. Phosphatidylcholine levels were significantly reduced in the bile from cancer patients when compared with bile from non-cancer patients (P=0.007).

CONCLUSION

These preliminary studies suggest that H and P NMR spectroscopy of bile may be used to detect differences in phospholipid content between cancer and non-cancer patients. This may have implications for the development of novel diagnostic strategies in hepatopancreaticobiliary cancers. Further larger-scale studies are warranted.

1H-Magnetresonanzspektroskopie (MRS) der Leber und von Lebermalignomen bei 3,0�Tesla

Use of whole-body MRI beyond 1.5 Tesla (T) has initiated a renaissance in spectroscopic procedures (MRS). The superior signal-to-noise ratio of clinical 3T tomographs allows reliable acquisition of MR spectra not only in fixed organs but also in targets moved by breathing such as the liver. The following contribution describes the principles of (1)H MRS and our own initial experiences with spectroscopy of the liver and hepatic malignant tumors with 3T whole-body MRI.